Topic Archives: NSAID

[ed note: We feature the musings of our favorite health and medicine writer, Michael Jorrin, a couple times a month, and we’ve taken the liberty of calling him “Doc Gumshoe” (he’s not a doctor). You’ll find no stock picks in his pieces, but hopefully will get plenty of insight into the medical matters he explains […]

Comments

  • Avatar

    $EYEG no position $IMMY long I will let Doc speak for himself. You need 3 different medications post op for cataract s...

  • Dr. KSS MD PhD

    $CATB is junk science. Shares will cool when people realize how flimsy the premise is. The lead drug is simply a conjug...

  • Avatar

    Will look into this again, Doc. I can tell you without further study that I would use a preparation of hyaluronic acid i...

  • SoGiAm

    athi $ PSDV – they made a bad deal with existing partner ALIM causing the shares to tank. I’m underwater on this an...

  • Avatar

    $PSDV NP $OCUL NP Sorry to hear the sad tale, athi. I've replaced my melted wings from ophtho investments gone bad way t...

  • JohnM

    Three interesting new technologies from SERAPH | The Angel's Advocate 1,First light-activated drug to treat pain A t...

  • Avatar

    Questioning the prognosis of @Fezziwig2008 (twitter handle) Long thesis? $CRBP Bear Thesis: The study itself seems ligh...

  • Dr. KSS MD PhD

    Meloxicam is an iv NSAID being developed by Recro Pharma ($REPH). Trevena is developing oliceridine, a mu opioid "b...

  • Michael Jorrin,

    If using Voltaren or some other topical analgesic means you can reduce or omit the oral NSAID, that would "mitigate" the...

  • Avatar

    NSAID side effect study results are in! A ten year, 24,000 patient study at the Cleveland Clinic has addressed safety c...

  • Avatar

    REPH np. I'm interested in it as well. Meloxicam is of course an NSAID (Non-Steroidal Anti-Inflammatory) just like Ibupr...

  • Dr. KSS MD PhD

    HN: Essentially, a war will soon be on between iv meloxicam (REPH) and iv ketorolac (Toradol). What investors need to kn...

  • Dr. KSS MD PhD

    I've not provided an update on Recro for some time. I remain long in this undervalued microcap, and applaud it finally h...

  • Avatar

    Hi danmcco. Although the idea of using punctal plugs to provide dropless and injectionless medication to the eye and sur...

  • Avatar

    $IMMY. Imprimis The volume of complaints from patients in my practice that involve money paid to obtain care has be...

  • drbonz

    Dr. KSS article on Recro (Reph) and it's IV meloxicam was very interesting and as always, a great read. Like the doc, I...

  • Dr. KSS, MD PhD

    Kenny: I am no expert on these, and Dr. Bonz knows far more about it than I do, but when I have patients with these, I t...

  • sogiam

    REPH- Recro Pharma Completes Acquisition of IV/IM Meloxicam and cGMP Manufacturing Facility and Business Unit From Alker...

  • Dr. KSS, MD PhD

    If anyone wants to see a totally cool 40-sec medical video, here is one. I love doing emergency endoscopy cases to stop ...

  • DBMD

    I'm not buying it no matter what. As a med student to staff physician I've been told how this new NSAID is better becaus...

  • Dr. KSS, MD PhD

    Thanks oleg. That's quite sad what your son and you are going through. Aplastic anemia usually strikes somewhat younger ...

  • Avatar

    Not sure about that Doc.... NIH Research: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3094288/ Wiki Report: Analges...

  • Dr. KSS, MD PhD

    To Tim Putnam: Thank you for reading and commenting. The maximum dose of tolerable safe ibuprofen varies quite a lot ...

  • karmaswimswami

    In addition to the closely-watched train of CHTP, the FDA is having another big meeting this week that has not been anno...

  • frank archambeau

    Dr. K I think synergy is valid expectation & then wonder about cocktail with Nsaid member. Small cost for "taste" of...

  • Avatar

    I have psioriatic arthritis, an autoimmune disease similar to RA. I have been through all the treatments in the article,...

  • Avatar

    Javelin is indeed an interesting company. Their flagship products is an injectable form of Dyclofenac--an NSAID called ...

  • Avatar

    The Therapeutic Goods Administration (TGA) cancelled the registration of lumiracoxib on Saturday due to reports of serio...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch